COMMUNIQUÉS West-GlobeNewswire
-
Shoreline Medical Administration, CHUM Health and Cellution Biologics Launch Elite Graft Program for Advanced Wound Care
13/10/2026 -
Eye2Eye Foundation Announces Free Thyroid Eye Disease Patient Seminars in Houston and Woodland Hills Featuring Dr. Raymond Douglas
13/10/2026 -
Sangamo Therapeutics Launches Auction Process for Clinical-Stage Chronic Neuropathic Pain Program
13/10/2026 -
Acquisition of Own Shares
13/10/2026 -
Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
13/10/2026 -
OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 27, 2026
13/10/2026 -
Rani Therapeutics to Participate in the Chardan Healthcare Conference
13/10/2026 -
CapsoVision to Present at the 20th Annual LD Micro Main Event
13/10/2026 -
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
13/10/2026 -
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
13/10/2026 -
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
13/10/2026 -
TRexBio Announces Closing of Initial Public Offering
13/10/2026 -
Texas Legends, Block Party Energy, and One Big Ribbon: Ally Medical ER Frisco Makes It Official
13/10/2026 -
BayCare Celebrates a Decade as a Fortune Best Workplace in Health Care™
13/10/2026 -
Standard Process® Announces Launch of MediHerb® GLP-1 Bitter Complex
13/10/2026 -
Assisting Hands Home Care - The Villages Doubles in Size in 2026 as Demand for In-Home Care Grows
13/10/2026 -
Lite Strategy Marks 15 Years of Litecoin with Launch of "Proof of Time" Public Industry Archive
13/10/2026 -
Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP
13/10/2026 -
DLH Publishes CEO Letter to Shareholders Highlighting “First 100 Days”
13/10/2026
Pages